- Home
- PENG vs OCS Comparison
PENG vs OCS Comparison
Compare PENG & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | OCS |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | PENG | OCS |
|---|---|---|
| Price | $20.37 | $20.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $27.50 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 798.6K | 114.7K |
| Earning Date | 01-06-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,368,794,000.00 | $991,999.00 |
| Revenue This Year | $8.56 | $14.53 |
| Revenue Next Year | $15.95 | $691.13 |
| P/E Ratio | $72.46 | ★ N/A |
| Revenue Growth | ★ 16.91 | N/A |
| 52 Week Low | $14.20 | $14.00 |
| 52 Week High | $29.80 | $23.08 |
Technical Indicators
Market Signals| Indicator | PENG | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 54.68 |
| Support Level | $19.65 | $20.18 |
| Resistance Level | $20.27 | $21.33 |
| Average True Range (ATR) | 0.64 | 0.72 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 26.71 | 54.38 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.